Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer Advanced 2026

Nicoletta Colombo

尼科莱塔·科伦坡

MD, PhD

🏢European Institute of Oncology (IEO), Milan(米兰欧洲肿瘤研究所)🌐Italy

Director, Gynecology Program; Professor of Gynecologic Oncology, University of Milan-Bicocca妇科项目主任;米兰比可卡大学妇科肿瘤学教授

67
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Nicoletta Colombo is Director of the Gynecology Program at the European Institute of Oncology (IEO), Milan, and a leading authority in gynecologic oncology globally. She was principal investigator of the GARNET trial establishing dostarlimab for mismatch repair-deficient recurrent endometrial cancer, and has contributed to pivotal trials in ovarian cancer including PARP inhibitor maintenance and immunotherapy combinations. She chairs ESMO gynecologic oncology guidelines.

Share:

🧪Research Fields 研究领域

Dostarlimab Endometrial Cancer多他利单抗子宫内膜癌
GARNET TrialGARNET试验
Ovarian Cancer Immunotherapy卵巢癌免疫治疗
Gynecologic Oncology ESMO GuidelinesESMO妇科肿瘤指南
PARP Inhibitors OvarianPARP抑制剂卵巢癌
MMR Deficiency错配修复缺陷

🎓Key Contributions 主要贡献

GARNET Trial: Dostarlimab in MMRd Endometrial Cancer

PI of the GARNET phase I trial demonstrating durable responses to dostarlimab (anti-PD-1) in mismatch repair-deficient recurrent or advanced endometrial cancer, leading to FDA approval and establishing immunotherapy as standard salvage for MMRd gynecologic cancers.

ESMO Gynecologic Oncology Clinical Practice Guidelines

Chairs and co-authors ESMO Clinical Practice Guidelines for endometrial and ovarian cancer, synthesizing global trial evidence into international treatment recommendations adopted by oncologists worldwide.

Representative Works 代表性著作

[1]

Dostarlimab for Recurrent Endometrial Cancer (GARNET)

Journal of Clinical Oncology (2021)

Phase I GARNET trial demonstrating durable antitumor activity of dostarlimab in MMR-deficient recurrent endometrial cancer, supporting regulatory approval.

[2]

ESMO Clinical Practice Guidelines: Newly Diagnosed and Relapsed Epithelial Ovarian Cancer

Annals of Oncology (2023)

Comprehensive ESMO guidelines synthesizing evidence on first-line and recurrence treatment for epithelial ovarian cancer including PARP inhibitors and bevacizumab.

🏆Awards & Recognition 奖项与荣誉

🏆ESGO Distinguished Service Award
🏆ESMO Gynecologic Oncology Working Group Chair
🏆AIRC Senior Investigator Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 尼科莱塔·科伦坡 的研究动态

Follow Nicoletta Colombo's research updates

留下邮箱,当我们发布与 Nicoletta Colombo(European Institute of Oncology (IEO), Milan)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment